Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10961983 | 0.98 | L3MBTL1 (0.37) | L3MBTL1PKMPREPHPGDGAA | |
| SCHEMBL14723681 | 0.97 | L3MBTL1 (0.35) | L3MBTL1PKMPREPHPGDSLC1A2 | |
| SCHEMBL417787 | 0.97 | L3MBTL1 (0.35) | L3MBTL1PKMPREPHPGDSLC1A2 | |
| SCHEMBL2325752 | 0.97 | L3MBTL1 (0.35) | L3MBTL1PKMPREPHPGDSLC1A2 | |
| Oxalic Acid SCHEMBL14858176 | 0.92 | PKM (0.34) | L3MBTL1PKMPREPHPGDSLC1A2 | |
| Oxalic Acid SCHEMBL1569384 | 0.92 | PKM (0.34) | L3MBTL1PKMPREPHPGDSLC1A2 | |
| Oxalic Acid SCHEMBL1569405 | 0.92 | PKM (0.34) | L3MBTL1PKMPREPHPGDSLC1A2 | |
| SCHEMBL352399 | 0.83 | HPGD (0.34) | L3MBTL1PREPHPGDGAAEPHX1 | |
| SCHEMBL24190369 | 0.81 | CHRNB2 (0.38) | L3MBTL1PKMSLC1A2SLC1A1 | |
| SCHEMBL4298689 | 0.81 | CHRNB2 (0.38) | L3MBTL1PKMSLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615886-A1 | [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | Warner-Lambert Company LLC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050137215-A1 | [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions | GUZZO PETER R (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2004092134-A1 | [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
| US-4503043-A | HYPOTENSIVES | WARNER-LAMBERT COMPANY (US) | 1985-03-05 | — | — | US | disclosed |
| EP-0058567-A1 | Substituted acyl derivatives of octahydro-1H-isoindole-1-carboxylic acids and esters | WARNER-LAMBERT COMPANY (US) | 1982-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137215-A1 | [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions | PPIC, PRAP1, PRRC2C | L3MBTL1 4211/4885PKM 1292/4885PREP 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.